Celcuity Inc. — Form SCHEDULE 13D/A
Filed July 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 72/100
What the filing says
On 7/14/2026, Baker Brothers Life Sciences L.P. sold 2,838,632 shares at $102.50/share (~$291M), and 667 L.P. sold 261,368 shares at the same price (~$26.8M). Combined sale represents ~3.1M shares (approximately 6.8% of current outstanding, based on holdings shown) at an aggregate value of ~$317.8M. Both are major shareholders with significant prefunded warrants and convertible note positions.
Why this rating
Large shareholder sales (~$318M aggregate) are 69% of company's ~$457.5M market cap—meaningful dilution signal; however, defined event with clear pricing shows orderly execution, not crisis. Material but not trajectory-altering alone.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.